Geneva Business School launches Switzerland’s first MBA in Biotech Management

Geneva Business School launches Switzerland’s first MBA in Biotech Management, blending business strategy with biotech innovation.

Geneva Business School (GBS) is set to launch in spring 2026 the first MBA in Biotech Management offered in Switzerland, a programme designed to integrate executive management training with the science-based realities of the biotech industry.

Developed in partnership with leading Swiss biotech companies, the 18‑month hybrid programme will be delivered entirely in English at GBS’s Geneva campus. It combines rigorous core courses in business fundamentals, such as strategy, finance, compliance, and market access, with biotech-specific modules including regulatory frameworks, quality assurance, commercial strategy, and emerging fields like AI in biotech, immunotechnology, and RNA therapeutics.

The curriculum is structured over three semesters:

• Semester 1 covers biotech business fundamentals—ranging from entrepreneurship in life sciences to biotech finance and brand management.
• Semester 2 focuses on biotech operations, legal and regulatory leadership, and strategic growth.
• Semester 3 centers on a capstone project and personal development tailored to biotech leadership, supported by executive coaching, industry networking, and placement services.

Entry requirements include a bachelor’s degree, professional experience (minimum three years), English proficiency (IELTS 6.5/TOEFL 85 or equivalent), a resume, two recommendation letters, and a written case study plus interview.

GBS highlights that this MBA was co-created with industry partners to ensure that students work on real biotech challenges and build practical expertise for leadership roles in biotech operations, business development, product management, regulatory affairs, venture capital, and more. The school’s accreditation includes IACBE and EduQua, reflecting international recognition for quality and relevance of its offerings.

“Switzerland is at the forefront of biotech innovation. This programme empowers leaders who can bring scientific breakthroughs to market,” said Francesco Derchi, MBA Director at GBS.

As biotech continues to address challenges in healthcare, sustainability, and technology, this MBA aims to produce globally connected graduates with the commercial acumen to transform research into impact.